Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo
Bosio, E., Beilharz, M.W., Watson, M.W. and Lawson, C.M. (1999) Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. Journal of Interferon & Cytokine Research, 19 (8). pp. 869-876.
*Subscription may be required
Oral administration of type I interferons (IFNs; murine IFN-α and IFN- β) reduces early replication of murine cytomegalovirus (MCMV) in both the spleen and liver of MCMV-infected BALB/c mice. Examination of a range of doses of IFN (1 to 1000 IU) showed that 10 IU administered daily for 1 week prior to virus infection was optimal for inhibition of MCMV replication. Furthermore, low-dose orally administered IFN (10 IU/day) was effective in mice challenged with lethal and sublethal virus inocula. The antiviral efficacy of low-dose orally administered IFN was not restricted by either the route of virus inoculation or the mouse genotype. Analysis by immunohistochemistry of IFN-α receptor-bearing cells of the gastrointestinal tract revealed predominant staining of perivascular smooth muscle and the lamina propria of the anterior tongue, small intestine and rectum. These tissues, dense in IFN-α receptor-bearing cells, are likely to be the sites of interaction of the orally administered IFNs with the mucosal immune system. In conclusion, we propose that low-dose oral use of type I IFN therapy may have broad applications in the treatment of CMV infections.
|Publication Type:||Journal Article|
|Murdoch Affiliation:||School of Veterinary and Biomedical Sciences|
|Publisher:||Mary Ann Liebert Inc.|
|Item Control Page|
Downloads per month over past year